Naloxone has been used in emergency medicine since the 1970s, according to the European Medicines Agency, yet its regulatory life in Europe has been oddly cautious. The medicine that reverses an opioid overdose is well understood to be safe, but in many EU countries it still requires a prescription. On October 15, the EMA's human medicines committee recommended changing that for one product.

What the committee recommended

The committee (CHMP) backed making Mundipharma's Nyxoid, a naloxone nasal spray, available without a prescription in all 27 EU member states plus Iceland, Liechtenstein and Norway, according to Citeline's report on the decision. The recommendation is not yet law. Until the European Commission issues a formal decision, the spray remains prescription-only, as a Polish pharmacy news site pointed out.

The step is unusual. If the Commission approves, Nyxoid would be only the seventh active substance to gain non-prescription status through the EU's centralised procedure since 2004, and the first since the premature ejaculation treatment Fortacin in 2020, Citeline reported. The change had been under evaluation since at least April, following a review by the Council of Europe's quality-medicines directorate (EDQM) that concluded nasal naloxone could be supplied without a prescription under certain conditions.

Nyxoid is intended for emergency treatment of known or suspected opioid overdose and is designed to be given by someone who is not a health professional, according to its product information.

Europe is already uneven

The EU-wide move would standardize a patchwork. Nasal naloxone is already available without a prescription in several European countries, including Finland, France, Ireland, Italy, Norway, Denmark and Sweden, per Citeline. Elsewhere, it depends on the country, the product and whether a take-home programme exists.

According to the EU drugs agency (EUDA), take-home naloxone programmes were reported in 19 European countries by 2025, though availability varies within and between countries. Among 10 countries that reported distribution data for 2024, eight reported more kits handed out than in 2023. Where programmes exist, nasal spray is the dominant format, used in 17 of them.

The gaps are specific. The EUDA singled out Bulgaria, where highly potent synthetic opioids are spreading in a context of limited harm reduction services, including the absence of take-home naloxone programmes. Fentanyl was involved in more than 100 drug-induced deaths in the country across 2024 and 2025, the agency reported.

The scale of the problem

The EUDA estimates at least 7,600 overdose deaths in the European Union in 2024, a figure that rises to about 8,300 if Norway and Türkiye are included. Opioids were involved in two-thirds of drug-induced deaths, usually alongside other substances. Overdose remains the main preventable cause of death among people who use drugs, the agency said.

New synthetic opioids add risk. In 2024, nitazenes were linked to 43 of 97 drug-induced deaths in Estonia and 36 of 77 in Latvia, the EUDA reported. Those clusters are small in absolute terms but show how quickly a potent new opioid can change the death toll in a single country.

Why prescription status matters

By definition, a person in an overdose cannot treat themselves. Help has to come from someone nearby, such as a friend, a relative or a hostel worker. A prescription system is built around the person who will take the drug, not the person who may have to use it on someone else. The AESGP, the association of Europe's self-care industry, welcomed the recommendation, noting that the ready-to-use spray can be given without medical training, buying time until emergency services arrive, Vital Signs reported.

Naloxone has a favorable safety record. Its product information states that it has not been shown to produce tolerance or cause physical or mental dependence, and that in the absence of opioids it has essentially no pharmacological activity. The main caution is that it can trigger acute withdrawal symptoms in someone who is dependent on opioids. The leaflet is also plain that it is not a substitute for emergency medical care.

What over-the-counter does not solve

Selling a spray without a prescription is not the same as getting it into the hands of the people who need it. Pharmacies may not be where people at risk are most easily reached, and a pharmacy price can be a barrier for some. A centralised switch decides the legal status of the product. It does not decide who pays, where it is stocked or whether national health systems will fund distribution through harm-reduction services.

That is why the EUDA keeps stressing programmes alongside access. Its latest report calls for expanding take-home naloxone and opioid agonist treatment together, and notes that coverage remains difficult to assess because reporting is incomplete.

The practical test comes after the Commission's decision. The first measure will be whether national authorities that already restrict naloxone change their rules, and the second whether the countries with the weakest harm-reduction systems use the new status to put kits in pharmacies and community services. A regulatory change will matter much less if it does not reach countries like Bulgaria, where take-home programmes are absent.

---